在宏球蛋白血症中检查点抑制
1Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
British journal of haematology
|November 6, 2024
概括
使用 pembrolizumab 的检查点抑制在 Waldenström 大球蛋白血症 (WM) 中显示出有前途. 这项研究研究了复发性/耐药性WM患者的rituximab和pembrolizumab.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 沃尔登斯特罗姆巨球蛋白血症 (WM) 是一种CD20+B细胞恶性瘤.
- WM具有免疫球蛋白M分泌骨髓透物和支持性的微环境.
- 在WM中指出了Upregulated Programmed Death 1 (PD-1) 表达,但检查点抑制的影响尚不清楚.
研究的目的:
- 评估Rituximab和Pembrolizumab联合治疗的安全性和有效性,用于复发性/耐药性WM患者.
- 评估检查点抑制在WM治疗中的作用.
主要方法:
- 进行了一项II期临床试验 (PembroWM).
- 这项研究涉及患有复发性/耐药的沃尔登斯特罗姆巨球蛋白血症的患者.
- 治疗包括Rituximab和Pembrolizumab. 这两种药物.
主要成果:
- 研究了rituximab和pembrolizumab的组合,以确定安全性和有效性.
- 来自PembroWM试验的结果为这种治疗方法提供了洞察力.
结论:
- 这项研究有助于理解WM的检查点抑制.
- 进一步的研究可能会阐明PD-1封锁在WM管理中的全部潜力.
相关概念视频
00:46Feedback Inhibition
53.7K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.7K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K